Biology Reference
In-Depth Information
lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes
mellitus. Metabolism 51:1348-1354
Inada H, Shindo H, Tawata M, Onaya T (1999) Cilostazol, a cyclic AMP phosphodiesterase
inhibitor, stimulates nitric oxide production and sodium potassium adenosine triphosphatase
activity in SH-SY5Y human neuroblastoma cells. Life Sci 65:1413-1422
Indolfi C, Di LE, Rapacciuolo A, Stingone AM, Stabile E, Leccia A, Torella D, Caputo R,
Ciardiello F, Tortora G, Chiariello M (2000) 8-chloro-cAMP inhibits smooth muscle cell
proliferation in vitro and neointima formation induced by balloon injury in vivo. J Am Coll
Cardiol 36:288-293
Ishikawa M, Yamada Y, Hirose C, Tujino D, Hoshi K, Saitou N (1997) The effects of cilostazol on
serum lipid metabolism and ASO in NIDDM with hypertriglyceridemia. Ther Res 18:198-204
Ishiwata N, Noguchi K, Kawanishi M, Asakura Y, Hori M, Mitani A, Ito Y, Takahashi K,
Nishiyama H, Shudo N, Takahashi S, Takahashi K, Tsuruzoe N, Nakaike S (2007) NT-702
(parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves
reduced walking distance and lowered hindlimb plantar surface temperature in a rat experi-
mental intermittent claudication model. Life Sci 81:970-978
Ito H, Hashimoto A, Matsumoto Y, Yao H, Miyakoda G (2010) Cilostazol, a phosphodiesterase
inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. J Cereb
Blood Flow Metab 30:343-351
Iwama D, Miyamoto K, Miyahara S, Tamura H, Tsujikawa A, Yamashiro K, Kiryu J, Yoshimura
N (2007) Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of
leukocyte-endothelial cell interactions. J Thromb Haemost 5:818-825
Jackson SP, Nesbitt WS, Westein E (2009) Dynamics of platelet thrombus formation. J Thromb
Haemost 7(Suppl 1):17-20
Kambayashi SY, Liu Y (2007) Bench to bedside: multiple actions of PDE3 inhibitor cilostazol. In:
Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and
disease. CRC Press, Boca Raton, FL, pp 627-648
Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F (2003) Cilostazol as a unique
antithrombotic agent. Curr Pharm Des 9:2289-2308
Kasseckert SA, Schafer C, Kluger A, Gligorievski D, Tillmann J, Schluter KD, Noll T, Sauer H,
Piper HM, Abdallah Y (2009) Stimulation of cGMP signalling protects coronary endothelium
against reperfusion-induced intercellular gap formation. Cardiovasc Res 83:381-387
Kemp-Harper B, Schmidt HH (2009) cGMP in the vasculature. Handb Exp Pharmacol 191:447-467
Keravis SAP, Favot L, Lugnier C (2007) Role of PDEs in vascular health and disease: endothelial
PDEs and angiogenesis. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide
phosphodiesterases in health and disease. CRC Press, Boca Raton, FL, pp 417-439
Kim KY, Shin HK, Choi JM, Hong KW (2002) Inhibition of lipopolysaccharide-induced
apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther
300:709-715
Kimura Y, Tani T, Kanbe T, Watanabe K (1985) Effect of cilostazol on platelet aggregation and
experimental thrombosis. Arzneimittelforschung 35:1144-1149
Koga Y, Kihara Y, Okada M, Inoue Y, Tochizawa S, Toga K, Tachibana K, Kimura Y, Nishi T,
Hidaka H (1998) 2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing
anti-thrombotic and anti-hyperplastic activities. Bioorg Med Chem Lett 8:1471-1476
Lee JH, Kim KY, Lee YK, Park SY, Kim CD, Lee WS, Rhim BY, Hong KW (2004) Cilostazol
prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and
suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation
in rats. J Pharmacol Exp Ther 308:896-903
Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP (2000) Oral Beraprost sodium,
a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized,
multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research
Group. Circulation 102:426-431
